REATA PHARMACEUTICALS INC-A (RETA) Stock Analyst Ratings
NASDAQ:RETA - Nasdaq - US75615P1030 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 53% to RETA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 175.9. This target is 2.05% above the current price.
RETA was analyzed by 15 analysts. The buy percentage consensus is at 53. So analysts seem to be rather neutral about RETA.
In the last month the buy percentage fell by 17 points. So the trust of analysts is decreasing.
RETA was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-08-15 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-08-01 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2023-08-01 | Citigroup | Downgrade | Buy -> Neutral |
| 2023-07-31 | Ladenburg Thalmann | Downgrade | Buy -> Neutral |
| 2023-07-31 | Baird | Maintains | Outperform -> Outperform |
| 2023-07-31 | Jefferies | Downgrade | Buy -> Hold |
| 2023-07-28 | Stifel | Downgrade | Buy -> Hold |
| 2023-07-24 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-07-06 | TD Cowen | Initiate | Outperform |
| 2023-06-29 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2023-06-28 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-06-28 | Barclays | Maintains | Overweight -> Overweight |
| 2023-06-12 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2023-05-11 | Barclays | Maintains | Overweight -> Overweight |
| 2023-04-13 | Stifel | Maintains | Buy |
| 2023-03-27 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-01 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-01 | Barclays | Maintains | Overweight |
| 2023-03-01 | Baird | Maintains | Neutral |
| 2023-03-01 | Goldman Sachs | Maintains | Buy |
| 2023-03-01 | Citigroup | Maintains | Buy |
| 2023-02-24 | Goldman Sachs | Maintains | Buy |
| 2022-11-28 | Goldman Sachs | Maintains | Buy |
| 2022-11-09 | Barclays | Maintains | Overweight |
| 2022-11-09 | Goldman Sachs | Maintains | Buy |
| 2022-11-09 | Citigroup | Maintains | Buy |
| 2022-10-19 | Guggenheim | Initiate | Buy |
| 2022-08-09 | Baird | Maintains | Neutral |
| 2022-05-27 | Citigroup | Maintains | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |